Tigecycline - A New Antibiotic in Infections Treatment

• Autorzy: Elżbieta Stefaniuk , Waleria Hryniewicz
• Języki publikacji: EN

Abstrakty

EN

Tigecycline, a member of a new class of antimicrobials (glycylcyclines), was shown to have expanded broad spectrum activity against most commonly encountered species responsible for community and hospital acquired infections, including Gram-positive and Gram-negative multidrug resistant bacterial strains.The aim of the study was to evaluate the activity of tigecycline against resistant bacterial strains commonly associated with nosocomial infections, including skin structure, subcutaneous layer and intra-abdominal infections.Material and methods. Ten general hospitals from different regions of Poland participated in the study. Antimicrobial susceptibility tests were carried for 539 isolates of different genus/species of bacterial strains isolated from patients hospitalized in hospitals throughout Poland. Minimal inhibitory concentrations (MICs) of tigecycline were determined using the broth dilution method.Results. Ten strains of 50 S. aureus isolates, i.e. 20%, were methicillin-resistant (MRSA). The lowest MIC90 values observed for tigecycline were (0.25 μg/ml); they were similar to the MIC50 for MSSA and MRSA.S. pneumoniae varied with respect to their susceptibility to penicillin. Twenty two percent of isolates (n=11) had decreased susceptibility to penicillin. However, all 50 strains of this species were susceptible to levofloxacin, vancomycin and linezolid. Tigecycline exhibited high activity against S. pneumoniae strains. Tigecycline MIC90 values for this group of strains were lower than MIC90 of the remaining antibiotics. One hundred percent of collected S. agalactiae strains were susceptible to all investigated antibiotics.Conclusion. The presented data indicate that tigecycline exhibits excellent inhibitory activity against nosocomial and community pathogens regardless of resistance patterns.

Słowa kluczowe

EN

tigecycline; bacterial pathogens; drug-resistance mechanisms; skin; subcutaneous layer and intra-abdominal infections

• Wydawca: Index Copernicus International
• Czasopismo: Polish Journal of Surgery
• Rocznik: 2007
• Tom: 79
• Numer: 9
• Strony: 587-593

Daty

wydano

2007-09-01

online

2008-02-11

Twórcy

autor

Elżbieta Stefaniuk

• Department of Epidemiology and Clinical Microbiology, National Medicines Insitute, Warsaw Kierownik

autor

Waleria Hryniewicz

• Department of Epidemiology and Clinical Microbiology, National Medicines Insitute, Warsaw Kierownik

Bibliografia

• Stein GE, Craig WA: Tigecycline: a critical analysis. Clin Infect Dis 2006. 43: 518-24.[PubMed]
• Stefaniuk E, Żurek E, Chmylak B i wsp.: Ogólnopolski Sprawdzian Wiarygodności Badań Mikrobiologicznych - POLMICRO 2005. Diagn Lab 2005; 42: 45-62.
• Clinical and Laboratory Standards Institute. Methods for Dilution Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard - Seventh Edition: M7-A7. 2006. Villanova, PA.
• European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Eucast Definitive Document E.Def 1.2. Clin Microbiol Infect 2000; 6: 503-508.
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Sixteenth informational supplement: M100-S16. 2006. Villanova, PA.
• Comité de l'Antibiogramme de la Société Française de Microbiologie (2005).
• Hryniewicz W, Sulikowska A, Szczypa K i wsp.: Rekomendacje doboru testów do oznaczania wrażliwości bakterii na antybiotyki i chemioterapeutyki - 2006. Narodowy Instytut Zdrowia Publicznego, 2006.
• Gorbach SL: Intra-abdominal infections. Clin Infect Dis 1993; 17: 961-65.[Crossref]
• Krobot K, Yin D, Zhang Q et al.: Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acqiured intraabdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004; 23: 682-87.
• Marshall JC, Innes M: Intensive care unit management of intra-abdominal infection. Crit Care Med 2003; 31: 1137-2228.
• Bradford PA, Weaver-Sands T, Petersen PJ: In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41: 315-32.
• Munoz-Price S, Lolans K, Quinn JP: Four cases of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections with tigecycline. Scand J Infect Dis 2006; 38: 1081-84.
• Saner FH, Heuer M, Rath PM et al.: Successful salvage therapy with tigecycline after linezolid failure in a liver transplant recipient with MRSA pneumonia. Liver Transpl 2006; 12: 1689-92.
• Ellis-Grosse EJ, Babinchak T, Dartois N et al.: The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41: S341-53.
• Babinchak T, Ellis-Grosse E, Dartois N et al.: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41: 334-67.
• Hoban DJ, Bouchillon SK, Johnson BM et al.: In vitro activity of tigecycline against 6792 Gramnegative and Gram-positive clinical isolates from the global tigecycline evaluation and surveillance trial (TEST Program), 2004). Diag Microbiol Infect Dis 2005; 52: 215-27.
• Betriu C, Culebras E, Gómez M et al.: In vitro activity of tigecycline against Bacteroides species. J Antimicrob Chemother 2005; 56: 349-52.[PubMed]

Identyfikatory

DOI

10.2478/v10035-007-0092-9